Education and academic degree
• Master degree: 06/09/2000: Master of Pharmacy, University of Ljubljana, Faculty of Pharmacy (Supervisor: Prof. Dr. Marija Sollner Dolenc). The title: The synthesis of benzoxazine fibrinogen receptor antagonists.
• PhD degree: 27/10/2004: Pharmacy, University of Ljubljana, Faculty of Pharmacy (Supervisor: Prof. Dr. Marija Sollner Dolenc). The title: Design and synthesis of integrin receptor modulators.
• Assist. Prof. habilitation: 2008
Academic-pedagogic work and employement
• 01/10/2000-31/10/2004: University of Ljubljana, Faculty of Pharmacy, Chair for Pharmaceutical Chemistry, Researcher in the Project group 0787-002. Assistant teacher for Pharmaceutical chemistry.
• 03-17/03/2002: University of Karlsruhe; Institut für Organische Chemie; bilateral colaboration with the group of Prof. Dr. Athanassios Giannis, work on in vitro assay for integrin receptor modulators.
• 01/11/2004-today: University of Ljubljana, Faculty of Pharmacy, Chair for Pharmaceutical Chemistry, Researcher in the Project group 0787-002. Assistant teacher and assistant professor for Pharmaceutical chemistry 3.
• 2004-2009 Work on integral European project: EUR-INTAFAR (Inhibition of New Targets for Fighting Antibiotic Resistance). Funded by: European Community Sixth Framework Programme (FP6), contract number (LSHM-CT-2004-512138).
• 2006-2008: lecturer on Medicinal faculty in Maribor, lecturer of Pharmacology in years 2005/2006 and 2006/2007.
• 04/06/2007-18/04/2008: Universita' di Milano, Dipartimento di Chimica Organica e Industriale, Milano, Italy, guest (post-doc) researcher in the group of Prof. Dr. Anna Bernardi.
• 2008-2011: lecturer on Master programme of Industrial Pharmacy (Pharmaceutical chemistry).
• 2008-today: coordinator on post-graduate PhD programme Biomedicine, Pharmacy sub-field (Molecular Basis of Pharmaceutical Chemistry, sub-coordinator of Module 1).
• 2010-2014 Work on integral European project: MAREX (Exploring Marine Resources for Bioactive Compounds: From Discovery to Sustainable Production and Industrial Applications). Funded by: European Community 7th Framework Programme (FP7), Project Reference: 245137 (http://cordis.europa.eu/fetch?CALLER=FP7_PROJ_EN&ACTION=D&RCN=95006). Contact person: TAMMELA Päivi.
• 2011-today: coordinator and lecturer on Uniform master’s programme of Pharmacy (Pharmaceutical Chemistry 3).
Organizational and leadership skills
• 15-27/09/2003: Postgraduate European Radiopharmacy Course, Block 1: Pharmacy, Ljubljana, Slovenia; Member of organising committee.
• 13-24/09/2004: Postgraduate European Radiopharmacy Course, Block 1: Pharmacy, Ljubljana, Slovenia; Member of organising committee.
• 11-22/09/2006: Postgraduate European Radiopharmacy Course, Block 1: Pharmacy, Ljubljana, Slovenia; Member of organising committee.
• 17-21/06/2007: Austrian-German-Hungarian-Italian-Polish-Slovenian 5th Joint Meeting on Medicinal Chemistry, Portorož, Slovenia; Member of organising committee.
• 13-15/05/10: Satellite symposium "Mental Disorders", 35. Assembly of SFD, Portorož, Slovenia; Moderator and president of programme committee.
• 29/9-1/10/2011: 4th BBBB-Bled International Conference on Pharmaceutical Sciences New Trends in Drug Discovery, Delivery Systems and Laboratory Diagnostics. Bled, Slovenia. Member of organising committee.
Supervising activities
• Assist. Prof. Dr. Marko Anderluh was a supervisor to 17 thesists from Uniform master’s programme of Pharmacy and Postgraduate study programme of Clinical Biochemistry. One thesis was awarded Faculty Prešeren Prize and one received Krka’s Prize for research achievements. (http://izumbib.izum.si/bibliografije/Y20111128121934-21456.html).
• Assist. Prof. Dr. Marko Anderluh is currently supervising 3 PhD students at doctoral study of Biomedicine, field of Pharmacy.
Working in expert commissions at home and abroad
• Assist. Prof. Dr. Marko Anderluh was a member of international commission for evaluation of PhD theses "Commissione giudicatrice per l’esame finale del Dottorato di Ricerca in Scienze Chimiche", Universita' di Milano, Dipartimento di Chimica Organica e Industriale, Milano, Italy, in 2009.
Description of current and past research projects
• Assist. Prof. Dr. Marko Anderluh is a member of the program group P1-0208 Pharmaceutical chemistry: design, synthesis and evaluation of substances for a period between 1999-2013. Within this program group he is primarily engaged in the design, synthesis and biological evaluation of antagonists of lectin DC-SIGN as potential antiviral agents. This studies are conducted as a part of the European program CARMUSYS (Carbohydrate as multivalent System Study Tools Tues pathogen Interactions with DC-SIGN) where he works as an external member and cooperates with the following researchers: Prof. dr. dr. Anna Bernardi, Universita di Milano, Italy, Dr. Javier Rojo Marcos, Instituto de Investigaciones Químicas, CSIC - Universidad de Sevilla, Spain et al. Franck Fieschi, Institut de Biologie Structural, CEA-CNRS-UJF, Grenoble, France. The result of this interdisciplinary and international project have been published in the six high-profile publications, of which 5 have been published since 2010.
By 2004, Assist. Prof. Dr. Marko Anderluh was engaged in the design, synthesis and biological evaluation of integrin receptor antagonists and antithrombotic compounds with dual mechanism of action. In addition to numerous publications, two national patents have been also awarded as a result of the project findings.
Assist. Prof. Dr. Marko Anderluh also explores methods for radiofluorination of various ligands as markers for positron emission tomography. Work is ongoing in collaboration with Assist. Prof. Dr. Sylvie Mavel, Laboratoire de Chimie Thérapeutique the Faculty of Pharmacy in Tours, France (Faculté de pharmacie, Tours, France).
Work on integral European project
• Assist. Prof. Dr. Marko Anderluh was involved in the European project: EUR-Intafar (inhibition of New Targets for Fighting Antibiotic Resistance). Funded by: European Community Sixth Framework Programme (FP6), Contract number (LSHM-CT-2004-512138). He has optimized synthetic route for the preparation of differently substituted benzylidenrhodanines. Based on this route, several substituted benzylidenrhodanines were synthesized and evaluated as potent Mur ligase inhibitors.
• Assist. Prof. Dr. Marko Anderluh is currently involved in the European project: MAREX (Exploring Marine Resources for Bioactive Compounds: From Discovery to Sustainable Production and Industrial Applications). Funded by: European Community 7th Framework Programme (FP7), Project Reference: 245137 (http://cordis.europa.eu/fetch?CALLER=FP7_PROJ_EN&ACTION=D&RCN=95006). Contact person: TAMMELA Päivi. The project has just started, so the appropriate publication of results is expected in the coming years.
• In the years 2009 and 2010 Assist. Prof. Dr. Marko Anderluh was a leader of the applied project led by the company Krka, d.d., where the aim was the innovative synthesis of substance vildagliptin. The project was successfully completed, and the invention was patented by an international patent application: ZUPET, Rok et al. SYNTHESIS AND USE OF VILDAGLIPTIN FOR THE PREPARATION OF PHARMACEUTICAL DOSAGE FORMS. Patent: WO/2011/012322, 2010, A2. http://worldwide.espacenet.com/publicationDetails/biblio?DB=EPODOC&II=5&adjacent=true&locale=en_EP&FT=D&date=20110203&CC=WO&NR=2011012322A2&KC=A2 |